Latest news with #OGM
Argaam
18-05-2025
- Business
- Argaam
SACO shareholders approve dividend freeze for 2024
Saudi Company for Hardware's (SACO) shareholders approved the board of directors' recommendation to withhold cash dividend for 2024 during the ordinary general meeting (OGM) held May 15, according to statement to Tadawul. Shareholders further approved authorizing the board to distribute interim dividends on a semi-annual or quarterly basis for 2025.
Yahoo
16-05-2025
- Business
- Yahoo
Information regarding the results of the vote on the resolutions presented (and all adopted) at the Annual General Meeting on May 15, 2025
Information regarding the results of the vote on the resolutions presented (and all adopted) at the Annual General Meeting on May 15, 2025 Voltalia (Euronext Paris, ISIN code: FR0011995588), an international player in renewable energies, held its Annual General Meeting on May 15, 2025, in Paris. A poll was held on each of the resolutions proposed. The results of the polls are set out below. Number of shareholders present, represented or voting by mail at the Ordinary General Meeting (OGM): 867 Number of shareholders present, represented or voting by mail at the Extraordinary General Meeting (EGM): 867 Number of voting rights exercisable as of May 15, 2025: 220,371,887 Total votes represented in the vote on the resolutions submitted to OGM: 202,370,496 Total votes represented in the vote on the resolutions submitted to EGM: 202,370,496 Results of the polls on the resolutions proposed under the jurisdiction of the Annual General Meeting: Ordinary resolutions Votes for Votes against Abstention Status Votes % Votes % Votes 1 Approval of the statutory financial statements for the year ended December 31, 2024 202,353,232 99.99% 4,984 0.01% 12,280 Agreed 2 Approval of the consolidated financial statements for the year ended December 31, 2024 202,352,506 99.99% 5,408 0.01% 12,582 Agreed 3 Allocation of net income for the year ended December 31, 2024 202,345,581 99.99% 11,409 0.01% 13,506 Agreed 4 Renewal of the term of office as director of Sarah Caulliez 191,539,101 95.46% 9,114,170 4.54% 1,717,225 Agreed 5 Appointment of a new director (Mr. Alexis Grolin) 191,963,604 95.67% 8,686,713 4.33% 1,720,179 Agreed 6 Appointment of a new director (Mr. Bertrand Cousin) 191,901,337 95.64% 8,749,796 4.36% 1,719,363 Agreed 7 Approval of the components of the compensation due or awarded to the President of the Board of Directors, Laurence Mulliez, for the 2024 financial year 185,896,774 92.19% 15,755,370 7.81% 718,352 Agreed 8 Approval of the compensation due or awarded to the Chief Executive Officer, Sébastien Clerc, for the 2024 financial year 188,753,931 94.39% 11,224,651 5.61% 2,391,914 Agreed 9 Vote on information relating to the 2024 compensation of the corporate officers (excluding executive corporate officers) set out in Article L22-10-9 of the French Commercial Code 186,355,873 93.99% 11,922,637 6.01% 4,091,986 Agreed 10 Approval of the 2025 compensation policy for corporate officers 200,220,113 99.91% 182,997 0.09% 1,967,386 Agreed 11 Approval of the 2025 compensation policy for the President of the Board of Directors 185,898,806 92.19% 15,748,751 7.81% 722,939 Agreed 12 Approval of the 2025 compensation policy for the Chief Executive Officer 191,759,291 95.68% 8,649,597 4.32% 1,961,608 Agreed 13 Determination of the overall compensation allocated to the members of the Board of Directors 200,218,372 99.91% 188,933 0.09% 1,963,191 Agreed 14 Authorization for the Board of Directors to purchase the Company's own shares 196,335,323 97.02% 6,028,019 2.98% 7,154 Agreed 15 Authorization to be granted to the Board of Directors to reduce the share capital by cancelling treasury shares 199,024,882 98.35% 3,337,323 1.65% 8,291 Agreed 16 Delegation of authority to the Board of Directors for the purpose of increasing the share capital without preferential subscription rights for a category of persons within the framework of implementing an equity or bond financing facility 183,223,915 90.54% 19,133,912 9.46% 12,669 Agreed 17 Delegation of authority to the Board of Directors for the purpose of increasing the share capital without preferential subscription rights for banks or financial institutions with the aim of promoting sustainable development in economic, social and/or environmental matters 183,221,130 90.54% 19,137,207 9.46% 12,159 Agreed 18 Delegation of authority to increase for the purpose of increasing the share capital, without preferential subscription for investors active in the field of energy, in particular renewable energies, and in the promotion of sustainable development in economic, social and/or environmental matters 183,222,922 90.54% 19,134,728 9.46% 12,846 Agreed 19 Delegation of authority to the Board of Directors to increase the share capital, with preferential subscription rights of the shareholders. 186,204,973 92.02% 16,158,574 7.98% 6,949 Agreed 20 Delegation of authority to the Board of Directors to increase share capital, with cancellation of shareholders' preferential subscription rights and public offering(s) (other than the offerings referred to in paragraph 1° of Article L. 411-2 of the French Monetary and Financial Code) 183,220,522 90.54% 19,138,867 9.46% 11,107 Agreed 21 Delegation of authority to the Board of Directors to increase share capital, with cancellation of shareholders' preferential subscription rights, in connection with offers referred to in paragraph 1° of Article L. 411-2 of the French Monetary and Financial Code. 182,792,794 90.52% 19,139,834 9.48% 437,868 Agreed 22 Delegation of authority to the Board of Directors to increase the number of securities to be issued in the event of a capital increase with or without preferential subscription rights 186,035,378 92.71% 14,627,440 7.29% 1,707,678 Agreed 23 Delegation of authority to issue ordinary shares and/or securities giving access to the Company's capital, in the event of a public offer with an exchange component initiated by the Company 183,599,179 90.73% 18,757,335 9.27% 13,982 Agreed 24 delegation of powers to increase the share capital to remunerate contributions in kind of equity securities or securities giving access to the capital of third-party companies outside a public exchange offer 185,946,332 91.89% 16,408,668 8.11% 15,496 Agreed 25 Setting the overall limits on the number of issues carried out by virtue of the above-mentioned delegations of authority 199,173,808 98.43% 3,181,897 1.57% 14,791 Agreed 26 Delegation of authority to be granted to the Board of Directors for the purpose of increasing the share capital by issuing shares and securities convertible to capital of the Company without preferential subscription rights for shareholders for the benefit of the employees who are members of the Group savings plan 202,309,113 99.98% 49,625 0.02% 11,758 Agreed 27 amendment of Article 12 of the Articles of Association to conform with the new applicable legal provisions 202,346,226 99.99% 12,445 0.01% 11,825 Agreed 28 amendment of Article 23 of the Articles of Association 'Loss of half the share capital' to confirm with the new provisions of Article L. 225-248 of the French Commercial Code 202,335,661 99.99% 14,195 0.01% 20,640 Agreed Next on the agenda: Q2 2025 revenues, on July 23, 2025 (after market close) About Voltalia ( Voltalia is an international player in renewable energies. The Group produces and sells electricity from its wind, solar, hydro, biomass and storage facilities. It has 3.3 GW of capacity in operation and under construction, and a portfolio of projects under development with a total capacity of 17.4 GW. Voltalia is also a service provider, supporting its renewable energy customers at every stage of their projects, from design to operation and maintenance. A pioneer in the business market, Voltalia offers a comprehensive range of services to businesses, from the supply of green electricity to energy efficiency services and the local production of its own electricity. With more than 2,000 employees in 20 countries on 3 continents, Voltalia has the capacity to act globally on behalf of its customers. Voltalia is listed on the Euronext regulated market in Paris (FR0011995588 - VLTSA) and is included in the Enternext Tech 40 and CAC Mid&Small indices. The company is also included, amongst others, in the MSCI ESG ratings and the Sustainalytics ratings. VoltaliaEmail: invest@ +33 (0)1 81 70 37 00 Press Relations - Jennifer +33 (0)1 56 88 11 19 Attachment Information regarding the results of the vote on the resolutions presented (and all adopted) at the Annual General Meeting on May 15, 2025Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
02-05-2025
- Health
- Yahoo
International Consortium for Optical Genome Mapping Publishes Expert Recommendations for Integration of OGM as a Standard-of-Care Cytogenetic Assay for Diagnostic Workflows in Blood Cancers
SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), today announced the publication in the American Journal of Hematology of expert recommendations from the International Consortium for Optical Genome Mapping (ICOGM) for the integration of OGM as a standard-of-care (SOC) cytogenetic assay for diagnostic workflows in various clinical settings. Nineteen (19) experts from the ICOGM, representing relevant multidisciplinary fields, conducted an in-depth review of the classification of hematolymphoid malignancies using the World Health Organization (WHO, 5th ed.) and ICC (International Consensus Classification) criteria and published studies of OGM performance to assess whether OGM could provide a comprehensive analysis of the genome sufficient for better diagnosis, prognosis and treatment compared to existing SOC workflows across several indications. Based on the assessment, the ICOGM developed a set of expert recommendations for OGM (A) as a first-line test in place of karyotyping, fluorescent in situ hybridization (FISH) and chromosomal microarray analysis (CMA) in some clinical settings; or (B) as an alternative to the traditional methods in other clinical settings when these traditional methods are insufficient. Summary of Key Recommendations for Clinical Use of OGM: A. OGM is recommended as a first-line test for AML, MDS, MPN, B-ALL, T-ALL, pediatric leukemias and unexplained eosinophilia and myeloid/lymphoid neoplasms with eosinophilia:OGM is recommended as a first-line cytogenetic tool in place of conventional karyotyping and FISH (except for rapid PML::RARA detection in APL) when high-resolution genome-wide structural variation (SV) detection is required. OGM allows for the identification of cryptic fusions of genes for which targeted therapy may be available (e.g. KMT2A, MECOM, NUP98) OGM avoids the need for large FISH panels or multiple orthogonal assays OGM's unbiased detection improves risk stratification and guides targeted therapy B. OGM is recommended as an alternative to karyotyping/FISH/CMA for CLL, Plasma cell neoplasms/Multiple Myeloma, aplastic anemia, bone marrow failure syndromes and germline predisposition syndrome: Conventional karyotyping fails or yields no metaphases FISH/CMA do not detect known abnormalities despite clinical suspicion Complex or ambiguous chromosomal abnormalities need resolution Low-frequency or rare hematologic malignancies require cost-effective broad analysis Additional structural variant data may impact diagnostic clarity or therapy decisions For CLL/SLL; OGM as a viable alternative to FISH and CMA, except for low-level TP53 deletions. For plasma cell disorders, OGM is recommended to be effective when used with CD138 enrichment "We believe this publication is a landmark for the global clinical cytogenomics community. The consensus from a global panel of experts confirms that OGM-based assays, like the LDTs we offer at Bionano Laboratories, can replace or be used to augment tests based on traditional methods. The drivers behind these recommendations are the ability of our OGM LDTs to yield higher diagnostic clarity within a simplified laboratory workflow that is more cost effective with a faster turnaround time. These expert recommendations establish that OGM-based LDTs are aligned with the latest diagnostic (WHO5, ICC) and prognostic (comprehensive cytogenetic scoring system (CCS), revised international prognostic scoring system (IPSS-R) and molecular international prognostic scoring system (IPSS-M)) classification systems for hematologic malignancies. It's a win for our laboratory, for clinicians and, more importantly, for patients," commented Dr Alka Chaubey, PhD, FACMG, chief medical officer of Bionano. For more information or to read the full publication, visit: About Bionano Laboratories: Lineagen, Inc. d/b/a Bionano Laboratories provides access to genetic answers and support utilizing cutting-edge technologies to advance the way the world sees the genome. Its clinical diagnostics services offer optical genome mapping (OGM) testing that combines a comprehensive testing portfolio with thoughtful and accessible support options. Bionano Laboratories also offers direct access to OGM for applications across basic, translational and clinical research. For more information, visit About Bionano Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company's mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services. For more information, visit or Forward-Looking Statements of Bionano Genomics This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'ability,' 'believe,' 'can,' 'could,' 'may,' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the ability and utility of OGM to be an alternative to traditional cytogenomic methods as described in the publication referenced in this press release; the ability and utility of OGM to become a SOC cytogenetic assay for diagnostic workflows in various clinical settings as described in the publication referenced in this publication; and the ability of OGM to be implemented in clinical settings. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the impact of adverse geopolitical and macroeconomic events, such as bank failures, the ongoing conflicts between Ukraine and Russia and in the Middle East and related sanctions, regional or global pandemics, uncertain market conditions, including tariffs and inflation, and supply chain disruptions on our business and the global economy; the failure of OGM to be an alternative to traditional cytogenomic methods as described in the publication referenced in this press release; the failure of OGM to become a SOC cytogenetic assay for diagnostic workflows in various clinical settings as described in the publication referenced in this publication; the failure of OGM to be implemented in clinical settings; the ability of the OGM workflow to offer the anticipated benefits for and contributions to the areas reported in the publication referenced in this press release; future recommendations contradicting the recommendations reported in the publication referenced in this press release; general market conditions; . All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise. CONTACTS Company Contact:Erik Holmlin, CEOBionano Genomics, Inc.+1 (858) 888-7610eholmlin@ Investor Relations:David HolmesGilmartin Group+1 (858) 888-7625IR@
Zawya
30-04-2025
- Business
- Zawya
Egypt: Rameda to pay $3.15mln cash dividends for 2024
The Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents' (Rameda) ordinary general meeting (OGM) approved the distribution of cash dividends valued at EGP 160 million for 2024 to shareholders over two equal installments, according to a bourse filing. The first payment will be in June 2025, while the second instalment will be in November 2025. The OGM also endorsed the distribution of bonus shares worth EGP 122.25 million, equivalent to 0.3236:1 share. Rameda posted a 58.2% year-on-year (YoY) uptick in consolidated profits attributable to the parent company in 2024 to EGP 387.366 million, versus EGP 244.859 million. © 2020-2023 Arab Finance For Information Technology. All Rights Reserved. Provided by SyndiGate Media Inc. (
Zawya
28-04-2025
- Business
- Zawya
Egypt: Delta Insurance's OGM greenlights $3.9mln cash dividends for 2024
Arab Finance: Delta Insurance's ordinary general meeting (OGM) approved the payment of cash dividends worth EGP 200 million or EGP 2 per share for 2024, according to a bourse disclosure. The dividends will be distributed over two equal instalments, with the first instalment to be paid within a month from the general assembly's meeting that was held on April 23rd, 2025. Meanwhile, the second instalment will be distributed at the end of August 2025. © 2020-2023 Arab Finance For Information Technology. All Rights Reserved. Provided by SyndiGate Media Inc. (
